Skip to content

A Multicenter, Randomized, Double-blind Pacebo-controlled Trial of Treatment Based on Disease-syndrome Combination for Reducing Acute Cardiovascular Events in Patients with Stable Coronary Heart Disease

A Multicenter, Randomized, Double-blind Pacebo-controlled Trial of Treatment Based on Disease-syndrome Combination for Reducing Acute Cardiovascular Events in Patients with Stable Coronary Heart Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13004370
Enrollment
Unknown
Registered
2013-12-28
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Intervention group:Yugeng tongyu decoction+ conventional western medicine treatment
control group:conventional western medicine treatment

Sponsors

China Academy of Chinese Medical Sciences Xiyuan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with identified myocardial infarction history, or coronary artery stenosis=50% on angioplasty or CTA examination, or keeping stable=1month after treatment of ACS(PCI or medicine intervention); (2) Aged between 18 and 75 years old; (3) Serum high-sensitivity C reactive protein level between 3 mg/L and 10 mg/L; (4) Patients providing written informed concents.

Exclusion criteria

Exclusion criteria: (1) Patients have a history of AMI, unstable angina, PCI or CABG within one month; (2) Combination with other heart desease or severe cardiopulmonary insufficiency; (3) Poor control of blood pressure (systolic pressure=160mmHg, or diastolic pressure =100mmHg); (4) Patients combined with acute cerebrovascular diseases; (5) Patients have a history of serious hepatic, renal, hematological,neurological,or severe psychiatric diseases; (6) Malignant arrhythmias (paroxysmal ventriculartachycardia) recurrent attacks; (7) women with pregnancy, planned pregnancy or lactating; (8) Subjects underwent surgical intervention on the skull or chest and abdomen within 4 weeks have a tendency to bleed; (9) Patients participated in other clinical trials within 1 month; (10) patients with allergy and are allergic to known components of the experimental.

Design outcomes

Primary

MeasureTime frame
cardiac death; Non fatal myocardial infarcion; coronary revascularization;

Secondary

MeasureTime frame
All cause of death;rehospitalization for ACS/heart failure/ malignant;Ischemic stroke;Other thrombotic complication;

Countries

China

Contacts

Public ContactDazhuo Shi

Xiyuan Hospital, China Academy of Chinese Medical Sciences

heartmail@263.net+86 010 62860499

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 12, 2026